PIPELINE > TRIAL OVERVIEW
Phase
1
Not Enrolling
An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2 (BRM) Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4 (BRG1) Alterations*
*
This clinical trial is being conducted in the United States and Japan.
†
LY4050784 is administered PO.
For information on trial enrollment, locations, and more, call
1-800-545-5979.
or visit www.clinicaltrials.gov for more information on this trial